Andhra Pradesh launches AI-assisted diabetic retinopathy screening at government hospitals
The Andhra Pradesh Department of Health launched an AI-assisted screening program for diabetic retinopathy at Government General Hospital in Guntur on June 10, with plans to expand to two additional hospitals by mid-June. The program uses the Madhunetra app developed by Wadhwani AI Foundation to analyze retinal images and determine disease severity without requiring specialist doctors on-site. The three-month pilot project aims to screen around 9,000 people and could expand access to eye care in areas lacking retinal specialists.
Andhra Pradesh's Department of Health, Medical Education and Family Welfare launched a pilot project using AI to screen for diabetic retinopathy at Government General Hospital in Guntur. The initiative will expand to Regional Hospital in Kurnool (June 13) and Government Regional Eye Hospital in Visakhapatnam (June 16). The program uses the Madhunetra app, developed by Wadhwani AI Foundation—which already provides AI services across 45 government medical colleges nationally—to analyze retinal images captured through fundus cameras and assess disease severity. The AI system determines whether patients need specialist consultation and the urgency of treatment. A key advantage is that optometrists with fundus cameras can conduct screening without on-site retinal specialists, potentially expanding access to diagnostic services. The three-month pilot is expected to screen approximately 9,000 people.
What different sources said
- The HinduCenter
AI-assisted eye screening begins at GGH in Guntur
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.